MedTrace Logo

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

NCT02057575 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 298

Last updated 2019-06-04

Study results available
· View outcomes & findings →

Summary

To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

PG324 Ophthalmic Solution 0.01%

1 drop in the evening (PM), once daily (QD), both eyes (OU)

DRUG

PG324 Ophthalmic Solution 0.02%

1 drop in the evening (PM), once daily (QD), both eyes (OU)

DRUG

Netarsudil (AR-13324) Ophthalmic Solution 0.02%

1 drop in the evening (PM), once daily (QD), both eyes (OU)

DRUG

Latanoprost Ophthalmic Solution 0.005%

1 drop in the evening (PM), once daily (QD), both eyes (OU)

Sponsors & Collaborators

  • Aerie Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Nancy Ramirez, M.S. · Aerie Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-06-30
Completion
2014-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057575 on ClinicalTrials.gov